Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma

Xin-Bin Pan
Shi-Ting Huang
Xiao-Dong Zhu
Department of Radiation Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People's Republic of China

Purpose: To assess the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in stage II nasopharyngeal carcinoma (NPC).

Methods: Stage II (2010 UICC/AJCC staging system) NPC patients treated between January 2007 and December 2014 were retrospectively analyzed. The NLR was calculated from peripheral blood cell counts before treatment. The optimal cut-off value of NLR was determined by receiver operating characteristic curve analysis. Survival rates were compared according to the NLR value. Multivariable Cox regression analyses were performed to assess the association between the NLR and overall survival (OS), locoregional-free survival (LRFS), and distant metastasis-free survival (DMFS).

Results: Two hundred and fifty-one stage II NPC patients were included in this study. The NLR was correlated with T stage (r=0.158, p=0.012). An NLR ≥2.92 was associated with poor 5-year OS (84.3% vs 97.4%, p=0.001) and LRFS (91.4% vs 98.4%, p=0.003). An NLR ≥2.82 was associated with poor 5-year DMFS (92.6% vs 98.2%, p=0.033). The multivariate Cox regression analysis showed that an NLR ≥2.92 was an independent prognostic biomarker in stage II NPC.

Conclusion: The NLR is an independent prognostic factor in stage II NPC.

Keywords: nasopharyngeal carcinoma, NPC, stage II, neutrophil-to-lymphocyte ratio, NLR

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southern China.1,2 With improvements in diagnosis, the incidence of stage II NPC has greatly increased. After treatment, the 5-year overall survival (OS) rate is nearly 90% for stage II NPC patients.3,4 However, approximately 10% of patients experience recurrence, distant metastasis, or death. Hence, it is important to identify patients with a high risk of recurrence and metastasis to optimize adjuvant treatments.

Until now, the prognosis of NPC mainly depends on the TNM stage. However, the TNM stage is based on anatomical structures and does not reflect the biological heterogeneity of stage II NPC. At present, the Epstein-Barr virus (EBV) DNA titer is the only proven biomarker with clinical utility in NPC.5–9 However, the EBV DNA test varies among different clinics. There is a critical need for additional prognostic biomarkers for stage II NPC.

Previous studies have indicated the association of the neutrophil-to-lymphocyte ratio (NLR) with prognosis in multiple tumor types.10–12 Some studies have focused on the prognostic impact of the NLR in NPC.13–16 However, the patients included in these studies were highly heterogeneous, mainly comprising those with locoregionally advanced NPC and metastatic disease. Moreover, the results differed between these
studies. Hence, this study was conducted to assess the effect of the pretreatment NLR on prognosis in stage II NPC patients.

Materials and methods
 Patients
We retrospectively analyzed stage II NPC patients (7th AJCC staging system\textsuperscript{17}) treated at the Affiliated Tumor Hospital of Guangxi Medical University between January 2007 and December 2014. The inclusion criteria were as follows: (1) pathologically confirmed NPC; (2) no prior malignancy; (3) no current antitumor therapy; and (4) no infection or symptoms of inflammation. The exclusion criteria were as follows: (1) patients with a self-reported acute infection or hematologic disorder and (2) a synchronous malignancy. Peripheral blood was collected before treatment. Neutrophils and lymphocytes were counted using a Sysmex XE-5000 automated hematology analyzer (Sysmex, Kobe, Japan). This study was approved by the Affiliated Tumor Hospital of Guangxi Medical University’s Ethics Committee. This study was performed according to compliance with the Declaration of Helsinki. But, informed consent was not available due to the retrospective nature. The data was anonymized or maintained with confidentiality.

Treatment, follow-up and endpoints
A detailed radiotherapy modality was published recently.\textsuperscript{18} Concurrent chemotherapy was scheduled on days 1, 22, and 43 with 80–100 mg/m\textsuperscript{2} of cisplatin for 1 or 3 days per cycle during radiotherapy. Adjuvant chemotherapy included 80–100 mg/m\textsuperscript{2} of cisplatin for 1 or 3 days and 600–750 mg/m\textsuperscript{2}/d of 5-fluorouracil via continuous intravenous infusion for 96 hrs or 120 hrs in a cycle of 28 days for 2–3 cycles. Chemotherapy was postponed or discontinued in patients who experienced serious toxicity and could not recover before the next scheduled cycle.

Patients were followed up every three months throughout the first two years, every six months for the next three years, and then annually. Endpoints included OS, locoregional-free survival (LRFS), and distant metastasis-free survival (DMFS).

Statistical analysis
The NLR was defined as follows: NLR = N/L, where N and L were the neutrophil and lymphocyte counts before treatment, respectively.

The correlation of the NLR with different prognostic factors was assessed by Spearman’s rank correlation coefficient. Prognostic factors were analyzed using the log-rank test in the univariate analysis; Cox regression analysis was used for the multivariate analysis. Receiver operating characteristic (ROC) curve analysis was used to assess the optimal cut-off points of the NLR for OS, LRFS, and DMFS. The Kaplan-Meier method was used to calculate survival rates. The log-rank test was used to assess differences between survival curves. Statistical analyses were performed using SPSS Statistics Version 23.0 software (IBM Co., Armonk, NY, USA). Two-tailed \( p \leq 0.05 \) was considered statistically significant.

Results
Patient characteristics
Two hundred and fifty-one stage II NPC patients were included in this study. Ninety-four patients received radiotherapy alone, 103 patients received concurrent chemotherapy, and 54 patients received concurrent chemotherapy followed by adjuvant chemotherapy. The follow-up rate was 96.81%. The median follow-up time was 64 months (range, 12–116 months). Patient characteristics are shown in Table 1.

Correlation of the NLR with different prognostic factors
The cut-off points determined by the ROC curve of the NLR for OS, LRFS, and DMFS were 2.92, 2.92, and 2.82, respectively. A high NLR (\( \geq 2.92 \)) was significantly correlated with T stage (\( r=0.158, p=0.012 \)). However, the NLR did not correlate with age, sex, pathology, N stage, or AJCC stage (Table 1).

NLR is correlated with prognosis
An NLR \( \geq 2.92 \) was associated with poor 5-year OS (84.3% vs 97.4%, \( p=0.001 \)) (Figure 1) and LRFS (91.4% vs 98.4%, \( p=0.003 \)) (Figure 2). The 5-year DMFS rate of the patients with an NLR \( \geq 2.82 \) was significantly lower than that of the patients with an NLR \( < 2.82 \) (92.6% vs 98.2%, respectively, \( p=0.033 \)) (Figure 3).

In the univariate analysis, a high NLR was correlated with poor OS (Table 2), LRFS (Table 3), and DMFS (Table 4). To correct for possible confounding factors, we used multivariate Cox regression to assess the effect of the NLR. The results showed that a high NLR (\( \geq 2.92 \)) was significantly correlated with poor OS (hazard ratio [HR] = 6.674, 95% confidence interval [CI]: 1.871–23.799, \( p=0.003 \)) (Table 2) and LRFS...
Discussion

Our findings indicate that the NLR is an independent prognostic factor for stage II NPC patients. An elevated NLR was significantly associated with poor OS, LRFS, and DMFS. Patients with a high NLR were more likely to develop recurrence and metastasis. These high-risk patients should receive optimized adjuvant treatments and close follow-up.

The prognosis of NPC patients mainly depends on the TNM stage. Stage II NPC is divided into three subgroups (T1N1, T2N0, and T2N1). Several studies have indicated that patients with T2N1 have poor survival.\textsuperscript{19,20} Xiao et al\textsuperscript{20} revealed that the 5-year OS rate was 91.3%, 85.8%, and 73.1% (\(p<0.05\)) for T1N1, T2N0, and T2N1, respectively. Luo et al\textsuperscript{19} reported that the 3-year OS rate was worse in T2N1 patients than in T1N1 and T2N0 patients (74.5 vs 100.0%, respectively; \(p=0.01\)). However, other studies have found that the survival rates were not different between the T1N1, T2N0, and T2N1 subgroups.\textsuperscript{3,21–23} The prognosis of the three subgroups remains controversial. These studies suggest that the TNM stage does not reflect the biological heterogeneity of stage II NPC. Additional prognostic biomarkers are needed to identify high-risk patients.

Several recent studies have suggested that the level of EBV DNA in the plasma, serum, or peripheral blood cells is a useful prognostic factor for NPC patients.\textsuperscript{5–9,24,25} However,

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|}
\hline
 \multicolumn{2}{|c|}{n} & \multicolumn{2}{|c|}{NLR} \\
\hline
 Age & & & \\
 \geq 44 & 127 (50.60\%) & 0.026 & 0.676 \\
 <44 & 124 (49.40\%) & & \\
\hline
 Sex & Female & 79 (31.47\%) & -0.076 & 0.229 \\
 & Male & 172 (68.53\%) & & \\
\hline
 Pathology & WHO II & 26 (10.36\%) & -0.032 & 0.615 \\
 & WHO III & 225 (89.64\%) & & \\
\hline
 T stage & T1 & 46 (18.33\%) & 0.158 & 0.012 \\
 & T2 & 205 (81.67\%) & & \\
\hline
 N stage & N0 & 56 (22.31\%) & 0.027 & 0.668 \\
 & N1 & 195 (77.69\%) & & \\
\hline
 AJCC & T2N0 & 56 (22.31\%) & 0.103 & 0.104 \\
 & T1N1 & 46 (19.52\%) & & \\
 & T2N1 & 149 (58.17\%) & & \\
\hline
\end{tabular}
\caption{Patient characteristics and correlation of the NLR with different prognostic factors}
\end{table}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure1.png}
\caption{Kaplan-Meier survival curve of five-year overall survival according to the neutrophil-to-lymphocyte ratio.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure2.png}
\caption{Kaplan-Meier survival curve of five-year locoregional-free survival according to the neutrophil-to-lymphocyte ratio.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure3.png}
\caption{Kaplan-Meier survival curve of five-year distant metastasis-free survival according to the neutrophil-to-lymphocyte ratio.}
\end{figure}
Table 2 Univariate and multivariate analyses of overall survival in stage II nasopharyngeal carcinoma patients

|                           | n               | Univariate (p) | Multivariate |
|---------------------------|-----------------|----------------|--------------|
|                           |                 |                | HR           | 95% CI        | p             |
| Age                       |                 |                |              |              |               |
| ≥44                       | 127 (50.60%)    | 0.859          | 1.006        | 0.935–1.083   | 0.864         |
| <44                       | 124 (49.40%)    |                |              |              |               |
| Sex                       |                 |                |              |              |               |
| Female                    | 79 (31.47%)     | 0.724          | 1.360        | 0.340–5.445   | 0.664         |
| Male                      | 172 (68.53%)    |                |              |              |               |
| Pathology                 |                 |                |              |              |               |
| WHO II                    | 26 (10.36%)     | 0.236          | 0.382        | 0.069–2.102   | 0.269         |
| WHO III                   | 225 (89.64%)    |                |              |              |               |
| AJCC                       |                 |                |              |              |               |
| T2N0                      | 56 (22.31%)     | 0.165          | 4.088        | 0.882–18.949  | 0.072         |
| T1N1                      | 46 (19.52%)     |                |              |              |               |
| T2N1                      | 149 (58.17%)    |                |              |              |               |
| Technique                 |                 |                |              |              |               |
| 2D-CRT                    | 73 (29.08%)     | 0.461          | 1.968        | 0.551–7.021   | 0.297         |
| IMRT                      | 178 (70.92%)    |                |              |              |               |
| Treatment                 |                 |                |              |              |               |
| RT                        | 94 (37.45%)     | 0.867          | 0.637        | 0.264–1.537   | 0.361         |
| CCRT                      | 103 (41.04%)    |                |              |              |               |
| CCRT+AC                   | 54 (21.51%)     |                |              |              |               |
| NLR                       |                 |                |              |              |               |
| ≥2.92                     | 41 (16.33%)     | 0.001          | 6.674        | 1.871–23.799  | 0.003         |
| <2.92                     | 210 (83.67%)    |                |              |              |               |

Abbreviations: NLR, neutrophil-to-lymphocyte ratio; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy; IMRT, intensity-modulated radiotherapy; 2D-CRT, two-dimensional conventional radiotherapy; HR, hazard ratio; CI, confidence interval.

Table 3 Univariate and multivariate analyses of locoregional-free survival in stage II nasopharyngeal carcinoma patients

|                           | n               | Univariate (p) | Multivariate |
|---------------------------|-----------------|----------------|--------------|
|                           |                 |                | HR           | 95% CI        | p             |
| Age                       |                 |                |              |              |               |
| ≥44                       | 127 (50.60%)    | 0.074          | 1.065        | 0.0994–1.142  | 0.075         |
| <44                       | 124 (49.40%)    |                |              |              |               |
| Sex                       |                 |                |              |              |               |
| Female                    | 79 (31.47%)     | 0.754          | 1.114        | 0.282–4.398   | 0.877         |
| Male                      | 172 (68.53%)    |                |              |              |               |
| Pathology                 |                 |                |              |              |               |
| WHO II                    | 26 (10.36%)     | 0.776          | 0.623        | 0.068–5.687   | 0.675         |
| WHO III                   | 225 (89.64%)    |                |              |              |               |
| AJCC                       |                 |                |              |              |               |
| T2N0                      | 56 (22.31%)     | 0.588          | 1.331        | 0.457–3.876   | 0.600         |
| T1N1                      | 46 (19.52%)     |                |              |              |               |
| T2N1                      | 149 (58.17%)    |                |              |              |               |

(Continued)
Table 3 (Continued).

|                        | n            | Univariate (p) | Multivariate |
|------------------------|--------------|----------------|--------------|
|                        |              |               | HR | 95% CI         | p  |
| Technique              |              |               | 0.369 | 0.464 | 0.107–2.007 | 0.304 |
| 2D-CRT                 | 73 (29.08%)  |               | 0.373 | 0.449 | 0.048–4.154 | 0.480 |
| IMRT                   | 178 (70.92%) |               | 0.328 | 1.065 | 0.366–3.104 | 0.908 |
| Treatment              |              |               | 0.963 | 0.828 | 0.348–1.966 | 0.668 |
| RT                     | 94 (37.45%)  |               | 0.963 | 0.828 | 0.348–1.966 | 0.668 |
| CCRT                   | 103 (41.04%) |               | 0.963 | 0.828 | 0.348–1.966 | 0.668 |
| CCRT+AC                | 54 (21.51%)  |               | 0.963 | 0.828 | 0.348–1.966 | 0.668 |
| NLR                    |              |               | 0.003 | 4.651 | 1.281–16.890 | 0.019 |
| ≥2.92                  | 41 (16.33%)  |               | 0.003 | 4.651 | 1.281–16.890 | 0.019 |
| <2.92                  | 210 (83.67%) |               | 0.003 | 4.651 | 1.281–16.890 | 0.019 |

Abbreviations: NLR, neutrophil-to-lymphocyte ratio; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy; IMRT, intensity-modulated radiotherapy; 2D-CRT, two-dimensional conventional radiotherapy; HR, hazard ratio; CI, confidence interval.

Table 4 Univariate and multivariate analyses of distant metastasis-free survival in stage II nasopharyngeal carcinoma patients

|                        | n            | Univariate (p) | Multivariate |
|------------------------|--------------|----------------|--------------|
|                        |              |               | HR | 95% CI         | p  |
| Age                    |              |               | 0.568 | 0.992 | 0.907–1.086 | 0.868 |
| ≥44                    | 127 (50.60%) |               | 0.568 | 0.992 | 0.907–1.086 | 0.868 |
| <44                    | 124 (49.40%) |               | 0.568 | 0.992 | 0.907–1.086 | 0.868 |
| Sex                    |              |               | 0.427 | 2.500 | 0.286–21.897 | 0.408 |
| Female                 | 79 (31.47%)  |               | 0.427 | 2.500 | 0.286–21.897 | 0.408 |
| Male                   | 172 (68.53%) |               | 0.427 | 2.500 | 0.286–21.897 | 0.408 |
| Pathology              |              |               | 0.400 | /     | /             | 0.988 |
| WHO II                 | 26 (10.36%)  |               | 0.400 | /     | /             | 0.988 |
| WHO III                | 225 (89.64%) |               | 0.400 | /     | /             | 0.988 |
| AJCC                   |              |               | 0.500 | 1.408 | 0.369–5.380 | 0.617 |
| T2N0                   | 56 (22.31%)  |               | 0.500 | 1.408 | 0.369–5.380 | 0.617 |
| T1N1                   | 46 (19.32%)  |               | 0.500 | 1.408 | 0.369–5.380 | 0.617 |
| T2N1                   | 149 (58.17%) |               | 0.500 | 1.408 | 0.369–5.380 | 0.617 |
| Technique              |              |               | 0.373 | 0.449 | 0.048–4.154 | 0.480 |
| 2D-CRT                 | 73 (29.08%)  |               | 0.373 | 0.449 | 0.048–4.154 | 0.480 |
| IMRT                   | 178 (70.92%) |               | 0.373 | 0.449 | 0.048–4.154 | 0.480 |
| Treatment              |              |               | 0.328 | 1.065 | 0.366–3.104 | 0.908 |
| RT                     | 94 (37.45%)  |               | 0.328 | 1.065 | 0.366–3.104 | 0.908 |
| CCRT                   | 103 (41.04%) |               | 0.328 | 1.065 | 0.366–3.104 | 0.908 |
| CCRT+AC                | 54 (21.51%)  |               | 0.328 | 1.065 | 0.366–3.104 | 0.908 |
| NLR                    |              |               | 0.033 | 4.399 | 0.855–22.635 | 0.076 |
| ≥2.82                  | 44 (17.53%)  |               | 0.033 | 4.399 | 0.855–22.635 | 0.076 |
| <2.82                  | 207 (82.47%) |               | 0.033 | 4.399 | 0.855–22.635 | 0.076 |

Abbreviations: NLR, neutrophil-to-lymphocyte ratio; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy; IMRT, intensity-modulated radiotherapy; 2D-CRT, two-dimensional conventional radiotherapy; HR, hazard ratio; CI, confidence interval.
EBV DNA was not routinely tested in our hospital from 2007 to 2010. Moreover, the EBV DNA test varies among different clinics. Thus, this study did not assess the prognostic implication of the EBV DNA titer. On the other hand, several inflammatory biomarkers, including the NLR,\textsuperscript{13–16} platelet-to-lymphocyte ratio (PLR),\textsuperscript{16} lymphocyte-to-monocyte ratio (LMR),\textsuperscript{26} prognostic nutritional index (PNI),\textsuperscript{27} and Glasgow Prognostic Score (GPS),\textsuperscript{15} were suggested to be associated with the prognosis of NPC patients. Among these inflammatory biomarkers, the NLR is simple to use in clinical practice, but the results varied between studies,\textsuperscript{13–16} thus, the NLR needs to be further investigated. Thus, we only assessed the prognosis of the NLR in stage II NPC patients.

Experimental evidence to support the prognostic significance of the NLR with cancer was previously reported. An elevated NLR is a marker of upregulated inflammatory processes within the host microenvironment. Inflammation promotes tumor progression and metastasis via the inhibition of apoptosis, the promotion of angiogenesis, and damage to DNA.\textsuperscript{28–30} Neutrophils support the initiation of metastasis by the preferential expansion of clones with high tumorigenicity.\textsuperscript{31}

However, the practical application of the NLR still needs to be better defined, especially in NPC patients. Sun et al\textsuperscript{32} reported that an NLR $\geq 2.7$ was significantly associated with short progression-free survival. Similar results were also suggested by other studies,\textsuperscript{13,15,16,33} although the NLR varied among these studies. On the other hand, Chua et al\textsuperscript{14} found that an NLR $\geq 3.0$ was not a prognostic factor in a pooled analysis of two randomized controlled trials. Possible explanations for previous contrary results include the following: (1) the patients included in these studies are highly heterogeneous; some studies included only metastatic NPC patients,\textsuperscript{15,33} whereas others assessed I-IV stage patients as a whole group,\textsuperscript{13,16} (2) the methods used to identify the value of the NLR were different; some studies used ROC curve analysis,\textsuperscript{13,15,16} whereas Chua et al\textsuperscript{14} used an NLR value of 3.0 directly, and/or (3) patients are also mostly retrospectively audited, thus likely having received nonstandardized treatments. The present study assessed the NLR only in stage II NPC patients. The patients included in this study were highly homogenous. Moreover, the optimal cut-off values of the NLR were determined by ROC curve analysis for different endpoints. Thus, the results of the current study are more credible.

The cut-off value of the NLR for OS was 2.92 for stage II NPC patients in our study. However, Jin et al\textsuperscript{33} reported that an NLR of 3.6 was associated with survival in metastatic NPC patients. Moreover, our study revealed that the NLR was positively associated with T stage. These results indicate that the NLR could contribute to patient stratification by adding a layer of information on disease burden. It is possible that the NLR is associated with the TNM stage. However, the conclusion should be further assessed considering the small sample size of the group of patients in T1 stage. Moreover, the NLR was not associated with N stage or the overall tumor classification stage.

This study had several limitations. First, the risk of treatment failure was very low in stage II NPC patients, which might have reduced the statistical power. Second, confounding factors may still have influenced this retrospective cohort study. Multicenter, large-scale prospective studies will be necessary to assess the precise cut-off values of the NLR as a prognostic marker for NPC.

In conclusion, our study suggests that the NLR is an independent prognostic factor for stage II NPC patients.

Acknowledgments
This study was supported by a grant from the Department of Education of Guangxi Zhuang Autonomous Region (No. KY2016LX029), a grant from Guangxi Medical University (No. GXMUYSF201519) and a grant from the Research and Development Project of Guangxi (No. 1598012-22).

Disclosure
The authors declare that they have no conflicts of interest in this work.

References
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–119.
3. Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era. Jpn J Clin Oncol. 2016;46(3):241–247. doi:10.1093/jjco/hvy192
4. Kang MK, Oh D, Cho KH, et al. Role of chemotherapy in Stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat. 2015;47(4):871–878. doi:10.4143/crt.2014.141
5. Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963–970. doi:10.1002/cncr.27853
6. Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003;98(1):74–80. doi:10.1002/cncr.11485
7. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000;60(24):6878–6881.

8. Lin JC, Chen KY, Wang WY, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol. 2001;19(10):2607–2615. doi:10.1200/JCO.2001.19.10.2607

9. Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder probe: real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1342–1348. doi:10.1016/j.ijrobp.2007.02.012

10. Shen L, Zhang H, Liang L, et al. Baseline neutrophil-lymphocyte ratio (>=2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295. doi:10.1186/s13041-014-0295-2

11. Ferrucci PF, Ascierto PA, Piggozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw016

12. Kawahara T, Yokomizo Y, Ito Y, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer. 2016;16:111. doi:10.1186/s12885-016-2134-3

13. Lu A, Li H, Zheng Y, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int. 2017;2017:3047802. doi:10.1155/2017/3047802

14. Chua ML, Tan SH, Kusumawidjaja G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer. 2016;67:119–129. doi:10.1016/j.ejca.2016.08.006

15. Chen C, Sun P, Dai QS, Weng HW, Li HP, Ye S. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma. PLoS One. 2014;9(11):e112581. doi:10.1371/journal.pone.0112581

16. Jiang Y, Qu S, Pan X, Huang S, Zhu X. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma. Oncotarget. 2018;9(11):9992–10004. doi:10.18632/oncotarget.24173

17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4

18. Pan XB, Chen KH, Huang ST, et al. Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. Oncotarget. 2017;8:78096.

19. Luo S, Zhao L, Wang J, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck. 2014;36(6):841–847. doi:10.1002/hed.23386

20. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(4):1070–1076. doi:10.1016/j.ijrobp.2008.09.008

21. Pan XB, Huang ST, Chen KH, Zhu XD. Chemotherapy use and survival in stage II nasopharyngeal carcinoma. Oncotarget. 2017;8(60):102573–102580. doi:10.18632/oncotarget.21751

22. Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82(1):327–333. doi:10.1016/j.ijrobp.2010.09.011

23. Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumour Biol. 2016;37(4):4429–4438. doi:10.1007/s13277-015-4266-5

24. Leung SF, Chan AT, Zee B, et al. Pretreatment quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003;98(2):288–291. doi:10.1002/cncr.11496

25. Du XI, Tang LL, Mao YP, et al. Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated radiotherapy in Stage II nasopharyngeal carcinoma. J Cancer. 2016;7(6):664–670. doi:10.7150/jca.14183

26. Jiang R, Cai XY, Yang ZH, et al. Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):237–246. doi:10.1186/s40880-015-0025-7

27. Oei RW, Ye L, Kong F, et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. Cancer Manag Res. 2018;10:2785–2797. doi:10.2147/CMAR.S171239

28. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446. doi:10.1038/nrc.2016.52

29. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–508. doi:10.1038/clpt.2009.254

30. DeNardo DG, Johansson M, Coussens LM. Inflaming gastrointestinal oncogenic programming. Cancer Cell. 2008;14(1):7–9. doi:10.1016/j.ccr.2008.06.010

31. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528(7582):413–417. doi:10.1038/nature16140

32. Sun W, Zhang L, Luo M, et al. Pretreatment hemato logic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2016;38(Suppl 1):E1332–E1340. doi:10.1002/hed.24224

33. Jin Y, Ye X, He C, Zhang B, Zhang Y. Pretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma. Head Neck. 2015;37(1):69–75. doi:10.1002/hed.23565